InternationalUSRemember you can easily switch between MIP US and MIP International at any time

MIP European Life Sciences Forum 2017 - Speakers

June 29, Le Méridien Piccadilly, London







Agenda





Delegates

Photos

Venue

Contact us

Speakers at the MIP European Life Sciences Forum 2017 included:


Johan Renes

Johan Renes

Partner
DLA Piper

Johan Renes is a qualified European patent attorney and provides general boardroom consultancy services to international clients in the life sciences sector. He has extensive experience in patent litigation and IP portfolio management, as well financing and IPOs in the bio-tech sector.

His clients range from Big Pharma to "series b" start-ups, as well as NGO's and universities. He has been involved in international litigation from the late eighties on antibodies, antisense RNA, therapeutic proteins, PCR and pharmaceutical small molecules.



Anneliese Hassenbuerger

Anne Hassenbuerger

Senior Patent Attorney
Novartis

Dr. Anneliese Hassenbuerger studied physics at the university in Munster, Germany. She worked at the Institute for Medical Physics and Biophysics dedicated to massspectrometry and the development of the MALDI method and received in 1993 her doctoral degree. Then she became a German and European patent attorney and 1997 she started working for the patent department of Novartis AG in Basel, Switzerland for the business unit CIBA Vision. In 2001 she moved to Wincor Nixdorf AG in Paderborn, Germany as head of the patent department. In the same position she worked for Leica Microsystems GmbH from 2007 to 2011 in Wetzlar, Germany.

Afterwards, she joined the law firm Viering, Jentschura and Partner in Dusseldorf, Germany, and since 2014 she is working again for Novartis Pharma AG in Basel.  She has special knowledge in the fields of medical technologies, digital medicine, mechatronics, optics and information technology.



Jennifer Roscetti

Jennifer Roscetti

Partner
Finnegan

Jennifer Roscetti is a partner in Finnegan, Henderson, Farabow, Garrett & Dunner Washington, DC office.  Roscetti practices patent litigation before US district courts and the US International Trade Commission (ITC).  She also represents clients before the US Court of Appeals for the Federal Circuit.  Roscetti's practice encompasses a range of technologies primarily focused on chemical subject matter such as pharmaceuticals, cosmetics, and specialty chemicals.  She has particular experience in representing pharmaceutical patent holders in Abbreviated New Drug Application (ANDA) litigations for blockbuster pharmaceuticals. 

Some of the products involved in the litigations on which Roscetti served as counsel include OxyContin®, Opana®, Nucynta® Zytiga®, Lovaza® and Evista®. Roscetti has had key responsibilities in all aspects of federal district court litigations, from the initial pleading stage through discovery, motions, claim construction, and trial. She also provides strategic guidance to clients on infringement, validity and enforceability issues.  She holds a JD from the University of Houston.



Erin Sommers

Erin Sommers

Partner
Finnegan

Erin Sommers is a partner in Finnegan, Henderson, Farabow, Garrett & Dunner, Washington, DC office.  Sommers is a registered US patent attorney who focuses her practice on patent litigation and practice before the US Patent and Trademark Office (USPTO), primarily in the chemical and pharmaceutical areas. She has gained litigation experience at all stages of district court Abbreviated New Drug Application (ANDA) litigation and appellate practice before the Federal Circuit.

She also assists clients with global management of their patent portfolios and prosecutes patent applications before the USPTO. She also represents clients before the Patent Trial and Appeal Board (PTAB) in post-grant proceedings.  Sommers holds a PhD from the University of Pennsylvania and a JD from Georgetown University.



Francis Tierney

Francis Tierney

Senior Patent Director
AstraZeneca

Francis Tierney has been working in the IP field since the late 1980s (all of it in ICI, Zeneca and AstraZeneca) and qualified as a patent attorney in the early 1990s.  Initially he was in the agrochemical area and specialised in plant fungicides and insecticides.  In late 1999 Tierney moved to AstraZeneca.  He has worked in several pharmaceutical therapeutic areas, predominantly in respiratory and neuroscience. 

For several years Tierney led AstraZeneca's small molecule patent due diligence work.  Tierney currently represents AstraZeneca on several external bodies including IP Federation, the IP Expert Group of EFPIA, and the IP group of ABPI.  In 2015 Tierney took on leadership of AstraZeneca's IP work in the Access to Medicines arena.



Niklas Mattsson

Niklas Mattsson

Partner
Awapatent

Niklas Mattsson drafts and prosecutes patent applications worldwide for local and international clients. He is also frequently involved in conducting infringement and validity investigations and freedom-to-operate analyses, and has been responsible for major due diligence projects for venture capital firms. Mattsson has also built up expertise in the procedures for SPCs (supplementary protection certificates) for pharmaceuticals throughout the EU.

Mattsson is often called upon to write articles and give lectures on the subject of biotech patents, both in Sweden and abroad. He is frequently engaged as a technical expert in patent litigation in Swedish courts, and has served as an expert witness in European patent law in a patent lawsuit in the USA. Areas of specialist technical expertise include protein engineering, biochemistry, genetics, biotechnology research tools, bioinformatics and polysaccharide chemistry. 



Sean Alexander

Sean Alexander

Senior Director
Eli Lilly

Sean Alexander is senior director – European [patent counsel at Eli Lilly & Company primarily working with the animal health division. Previously, Alexander was a partner at Gowling WLG in Canada supporting clients in the biopharmaceutical, medical device, and greentech sectors.

Alexander is part of the team at Lilly planning for the implementation of the Unitary Patent and the Unified Patent Court. In addition to being a European patent attorney, Alexander is a registered patent agent in Canada and the United States.
 



Luke Kempton

Luke Kempton

Partner
Gowling WLG

Luke Kempton has a PhD in biochemistry and has been active in the biotech/ pharmaceutical sector for about 20 years. He has both contentious and non-contentious experience in the sector.

He has acted for clients in patent proceedings before the United Kingdom intellectual property office, the patents county court, the patents court and the court of appeal as well as coordinating pan-European patent litigation proceedings relating to pharmaceutical and biotech products. In addition, Kempton has acted for big pharma, biotech companies and academic organisations in numerous drug acquisition, collaboration and licensing deals. He also advises on all types of agreements related to the pharmaceutical sector including clinical trial agreements, MTAs, manufacturing and supply agreements, CDAs and co-promotion agreements.
 
Kempton also has considerable experience of pharmaceutical regulatory issues, including judicial review proceedings in relation to MHRA decisions.



Paul Chapman

Paul Chapman

Head of legal
Avidity IP

Paul Chapman has almost 30 years’ experience of working in Intellectual property in the life sciences field. He began his career working in private practice in the 1980s, during the early days of the biotech industry. He then spent several years in house in a multinational pharmaceutical company, which gave him a useful perspective on the commercial importance of IP, both from the point of view of protecting new products and also clearing a path for a company’s commercial activities. He then returned to private practice and spent over 20 years at a major London firm, 17 of them as a partner.

Chapman has worked for individual clients, for start-up companies and SMEs, for universities and for larger corporate clients. His experience ranges across all areas of IP including, initial drafting and prosecution of patents, developing and managing patent portfolios, developing IP strategies, IP due diligence and IP transactional work, including stock exchange listings. As well as these he also has a wealth of experience in EPO opposition and appeal proceedings.

In terms of technology Chapman’s practice covers all the “conventional” aspects of life sciences, from NCEs through gene technologies, immunology, pharmaceutical formulations, drug delivery technologies, manufacturing processes and medical devices. Particular highlights include working on the original PCR patent filings before the EPO, the Harvard mouse case, which helped define the patentability of animals before the EPO and working on the original Roslin Institute case covering the cloning of Dolly the sheep.
 



 

Sponsors

Avidity IP

Bristows

Dechert LLP

Finnegan

Gowling WLG

Powell Gilbert







profile

Managing IP

ManagingIP

ManagingIP profile

Yohan Liyanage of Linklaters says the Australian concept of "hottubbing" of experts "is something that has just com… https://t.co/1WOz8PtP6K

Dec 8 2017 09:48 ·  reply ·  retweet ·  favourite
ManagingIP profile

Nokia’s Adrian Howes discussing Huawei v ZTE in panel on FRAND and SEPs. “One of the big things coming out of the C… https://t.co/9qqJX1WIpR

Dec 8 2017 05:49 ·  reply ·  retweet ·  favourite
ManagingIP profile

Maximillian Haedicke of University of Freiburg reveals the equivalent of tea leaf reading in Germany is called coff… https://t.co/GNi9hYfKa4

Dec 8 2017 03:18 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

null null null

End of Year 2017

Taking a wrecking ball to the IPR system

The lawyer behind Allergan’s controversial transfer of patents to a Native American tribe says others are “lining up to do deals”. But, Michael Loney asks, will the PTAB rule that sovereign immunity applies in these types of deals?



Most read articles

Supplements